| Source: |
| Type: |
| GSK3β is a crucial member of the Wnt/β-catenin-, hedgehog (Hh)-, notch- and c-myc-mediated major pro-oncogenic pathways, while also being a negative regulator of epithelial–mesenchymal transition (EMT). Accumulating evidence defines GSK3β as a potential therapeutic target in cancer, thus encouraging the development of GSK3β inhibitors for cancer treatment. Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis. Its expression and activity have been implicated in several types of cancer, often with varying prognostic implications. In many cancers, decreased GSK-3β activity is associated with poor prognosis, while in others, increased activity may correlate with aggressive disease. |
| Osteosarcoma is a type of cancer that starts in the bones. It is the most common type of bone cancer, and it usually affects children and young adults, although it can occur at any age. Osteosarcoma typically develops in the long bones of the body, such as the arms and legs, but it can also occur in other bones, including the pelvis and jaw. |
| 2844- | FIS, | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
| - | in-vitro, | OS, | U2OS |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:46 Cells:% prod#:% Target#:385 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid